| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1097-0142(19940701)74:1<16::AID-CNCR2820740105>3.0.CO;2-V |
| P698 | PubMed publication ID | 7516263 |
| P2093 | author name string | R Bader | |
| K Boudjema | |||
| A M Weiss | |||
| M A Bigard | |||
| F Dumas | |||
| J P Bronowicki | |||
| D Vetter | |||
| M Doffoel | |||
| J J Wenger | |||
| P Boissel | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 16-24 | |
| P577 | publication date | 1994-07-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients | |
| P478 | volume | 74 |
| Q50955798 | A high value of serum des-γ-carboxy prothrombin before hepatocellular carcinoma treatment can be associated with long-term liver dysfunction after treatment. |
| Q73789503 | Acute renal failure after transarterial chemoembolization progressing to chronic renal failure in hepatocellular carcinoma |
| Q46569847 | Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma |
| Q74646915 | Arterial hepatic embolization of unresectable hepatocellular carcinoma using a cyanoacrylate/lipiodol mixture |
| Q73044456 | Arteriovenous shunting in hepatocellular carcinoma: its prevalence and clinical significance |
| Q42231021 | Chemoembolisation with lipiodol and doxorubicin: applicability in British patients with hepatocellular carcinoma |
| Q78418406 | Chemoembolization for hepatocellular carcinoma: where does the truth lie? |
| Q34922680 | Chemoembolization of hepatocellular carcinoma |
| Q37161614 | Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study |
| Q26471711 | Combination of three-dimensional conformal radiotherapy and transcatheter arterial chemoembolisation versus transcatheter arterial chemoembolisation for primary hepatocellular carcinoma |
| Q35621307 | Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. |
| Q53557508 | Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. |
| Q71458879 | Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma |
| Q35962165 | Current and future treatment modalities for hepatocellular carcinoma |
| Q44481786 | Diagnosis of and therapy for hepatocellular carcinoma |
| Q36834223 | Ethanol injection for the treatment of hepatic tumours |
| Q34580237 | Hepatic arterioportal shunts: dynamic CT and MR features |
| Q28202929 | Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes |
| Q33932036 | Hepatic malignancies |
| Q35162986 | Impact of transarterial therapy in hepatitis C-related hepatocellular carcinoma on long-term outcomes after liver transplantation |
| Q92323533 | Is the treatment outcome of hepatocellular carcinoma inferior in elderly patients? |
| Q76383775 | Liver transplantation for hepatocellular carcinoma: a single European centre experience |
| Q41468544 | Liver-spleen infarcts following transcatheter chemoembolization: a case report and review of the literature on adverse effects |
| Q37062226 | Local recurrence of hepatocellular carcinoma after segmental transarterial chemoembolization: risk estimates based on multiple prognostic factors |
| Q34027985 | Localized hepatocellular carcinoma: therapeutic options |
| Q31046676 | Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective |
| Q83816502 | Management of hepatocellular carcinoma |
| Q37063190 | Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization |
| Q33185268 | New interventions for liver tumors |
| Q33381184 | Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience. |
| Q41459549 | Nonresectional therapies for hepatocellular carcinoma |
| Q37578521 | Nonsurgical treatment for localized hepatocellular carcinoma. |
| Q55068027 | Particle embolization for hepatocellular carcinoma. |
| Q36140437 | Predictors of hepatic decompensation after TACE for hepatocellular carcinoma |
| Q39420870 | Prospective comparison of transcatheter arterial chemoembolization with Lipiodol-epirubicin and Lipiodol-cisplatin for treatment of recurrent hepatocellular carcinoma |
| Q28487832 | Reduction in non-protein respiratory quotient is related to overall survival after hepatocellular carcinoma treatment |
| Q73246597 | Regional Therapy of Hepatic Malignancies |
| Q37155122 | Risk factors for local tumor recurrence after segmental transarterial chemoembolization for hepatocellular carcinoma: the importance of tumor located in the segmental border zone |
| Q64086795 | Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization |
| Q42502371 | Short-term reductions in non-protein respiratory quotient and prealbumin can be associated with the long-term deterioration of liver function after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma |
| Q71052784 | Surgical treatment strategy for patients with stage IV hepatocellular carcinoma |
| Q26996805 | The role of interventional radiology in the management of hepatocellular carcinoma |
| Q83423525 | Transarterial chemoembolization for hepatocellular carcinoma |
| Q35268118 | Transarterial chemoembolization in patients with hepatocellular carcinoma: predictors of survival |
| Q50514042 | Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. |
| Q34702094 | Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations |
| Q58236345 | Transcatheter Arterial Chemoembolization in Inoperable Hepatocellular Carcinoma: Four-year Follow-up |
| Q91676153 | Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults |
| Q40637515 | Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma |
| Q80899874 | Transient hepatic attenuation difference (THAD) following transcatheter arterial chemoembolization for hepatic malignancy: changes on serial CT examinations |
| Q71972322 | Treatment of hepatocellular carcinoma: a single-center experience |
| Q39443494 | Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients. |
| Q40660458 | Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. |
| Q36325322 | Use of the triaxial microcatheter method in super-selective transcatheter arterial chemoembolisation for hepatocellular carcinoma |
Search more.